Report Summary
During 2011 we witnessed the segmentation of the biotechnology industry as had long been forseen, drawn farther afield from its initial drug focus into areas such as “cleantech” and chemical manufacturing.While American Recovery and Reinvestment Act (ARRA) funds helped foster drug research and development, we noticed surprising emphasis on low-possibility-of-success (POS) areas such as antineoplastic and immunomodulating agents, contrasting with smaller sums being sent into higher POS fields, such as acute diseases or dermatology. This somewhat swinging-for-the-fences mentality has a rationale in that if successful these products have much lower post launch competition. But if uncoupled to creative thinking at the R&D stage, one wonders what the ultimate ROI will be for taking this risk, and if patent expiration desperation is fueling this trend. Perhaps significantly, the sports world has names and faces of major league pitchers who have gone ahead with stem cell treatments, with the hopes of resurrecting lucrative careers. Mainstream acceptance of the risk involved in immature therapeutics surely paves the way for more clinical trials and regulatory urgency.Regarding segmentation, we see many patents and venture capital dollars flowing into synthetic biology applications and “plants engineered to replace oil” efforts, such as algae biofuels and synthetic photosynthesis. The term “Biobrick” has come into common usage and will certainly not fade anytime soon.This Biotechnology Research Review provides a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision making since BCC was founded in 1971.
It includes highlights from the following reports published in 2011:
Published: January 2012 No. of Pages: 191
Price: Single User: US $ 850 Corporate User: US $ 1400
- The global market for sample preparation reagents and products used in life science research was $2.9 billion in 2010 and is expected to increase to $3.6 billion by 2011. The market is forecast to reach $8.4 billion by 2016, increasing at a compound annual growth rate (CAGR) of 18.8%.
- The global biobanking market was $141 billion in 2010 and is projected to expand by 30% between 2010 and 2015, increasing at a CAGR of 5.4%.
- The global RNAi drug delivery market was worth $7 billion in 2010 and is expected to grow to nearly $24.1 billion by 2015, increasing at a five-year CAGR of 27.9%.
During 2011 we witnessed the segmentation of the biotechnology industry as had long been forseen, drawn farther afield from its initial drug focus into areas such as “cleantech” and chemical manufacturing.While American Recovery and Reinvestment Act (ARRA) funds helped foster drug research and development, we noticed surprising emphasis on low-possibility-of-success (POS) areas such as antineoplastic and immunomodulating agents, contrasting with smaller sums being sent into higher POS fields, such as acute diseases or dermatology. This somewhat swinging-for-the-fences mentality has a rationale in that if successful these products have much lower post launch competition. But if uncoupled to creative thinking at the R&D stage, one wonders what the ultimate ROI will be for taking this risk, and if patent expiration desperation is fueling this trend. Perhaps significantly, the sports world has names and faces of major league pitchers who have gone ahead with stem cell treatments, with the hopes of resurrecting lucrative careers. Mainstream acceptance of the risk involved in immature therapeutics surely paves the way for more clinical trials and regulatory urgency.Regarding segmentation, we see many patents and venture capital dollars flowing into synthetic biology applications and “plants engineered to replace oil” efforts, such as algae biofuels and synthetic photosynthesis. The term “Biobrick” has come into common usage and will certainly not fade anytime soon.This Biotechnology Research Review provides a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision making since BCC was founded in 1971.
It includes highlights from the following reports published in 2011:
- Polymerase Chain Reaction (PCR) Technologies and Global Markets
- Biobanking: Technologies and Global Markets
- Global Biochip Markets: Microarrays and Lab-on-a-Chip
- Next-Generation Cancer Diagnostics: Technologies and Global Markets
- RNAi Drug Delivery: Technologies and Global Markets
- Stem Cell Therapeutics for Oncology: Technologies and Global Markets
- Flow Cytometry: Products, Technologies and Global Markets
- Sample Preparation in Genomics, Proteomics, and Epigenomics: Global Markets
Published: January 2012 No. of Pages: 191
Price: Single User: US $ 850 Corporate User: US $ 1400
Table Of Contents
Chapter- 1: 2011 BIOTECHNOLOGY RESEARCH REVIEW - Complimentary 2
FOREWORD
Chapter- 2: SAMPLE PREPARATION IN GENOMICS, PROTEOMICS, AND EPIGENOMICS: GLOBAL MARKETS (BIO089A) 16
INTRODUCTION
SUMMARY
OVERVIEW
MAJOR TRENDS AND DRIVERS IN THE SAMPLE PREP SEGMENT OF LIFE SCIENCE TOOLS INDUSTRY
GOVERNMENT POLICIES AND FUNDING
MAIN MARKET PARTICIPANTS IN THE SAMPLE PREP INDUSTRY
GEOGRAPHIC DISTRIBUTION OF THE SAMPLE PREP MARKET
TECHNOLOGY PATENTS IN THE SAMPLE PREP INDUSTRY
Chapter- 3: FLOW CYTOMETRY: PRODUCTS, TECHNOLOGIES AND GLOBAL MARKETS (BIO085A) 24
INTRODUCTION
SUMMARY
MARKET DRIVERS
RESTRAINTS
OPPORTUNITIES
MARKET OVERVIEW
EVOLUTION OF FLOW CYTOMETRY
FLOW CYTOMETRY CAPABILITY ANALYSIS
ANALYSES: KEY PLAYERS, COMPETITORS, AND MARKETS
EMERGING ECONOMIES AND TECHNOLOGY ADOPTION
STRATEGIC RECOMMENDATIONS
PATENT ANALYSIS
Figure 9 : PATENT ANALYSIS BY TYPE OF PRODUCT, 2008–2010
Table L9 :
Figure 10 : PATENTS BY GEOGRAPHY, 2008–2010
Table L10 :
Chapter- 4: BIOBANKING TECHNOLOGIES AND GLOBAL MARKETS (BIO084A) 21INTRODUCTION
SUMMARY
OVERVIEW
MODERN BIOBANKS—PUBLIC SECTOR
BIOBANKING COSTS
DRIVERS OF BIOBANKS EXPANSION
BARRIERS TO BIOBANKS EXPANSION
BIOBANKING TRENDS AND FORECAST
FORECAST FOR BIOBANK INVOLVEMENT IN FUTURE BIOMEDICAL DISCOVERIES
Chapter- 5: NEXT-GENERATION CANCER DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS (BIO081A) 14
INTRODUCTION
SUMMARY
OVERVIEW
MARKET POTENTIAL OF NEXT-GENERATION CANCER DIAGNOSTICS
FORCES DRIVING MARKET GROWTH
NEXT-GENERATION CANCER DIAGNOSTICS PLATFORMS
NEXT-GENERATION CANCER DIAGNOSTICS PRODUCT LIFE CYCLE STATUS
NEXT-GENERATION CANCER DIAGNOSTICS INDUSTRY
Table 16 : NEXT-GENERATION CANCER DIAGNOSTICS INDUSTRY
Chapter- 6: RNAI DRUG DELIVERY: TECHNOLOGIES AND GLOBAL MARKETS (BIO076A) 44
INTRODUCTION
SUMMARY
RNAI DRUG DELIVERY
CHALLENGES TO OVERCOME IN DELIVERING RNAI
DELIVERY TECHNIQUES
SUMMARY
Chapter- 7: STEM CELL THERAPEUTICS FOR ONCOLOGY: TECHNOLOGIES AND GLOBAL MARKETS (BIO075A) 21
INTRODUCTION
SUMMARY
OVERVIEW
TYPES OF CANCER
DEFINITION OF THE INDUSTRY
IMPORTANCE OF THE INDUSTRY
PRODUCT LIFE CYCLES
DEVELOPMENT OF STEM CELLS IN ONCOLOGY
FUTURE DEVELOPMENTS
WITH AN EYE TOWARD THE FUTURE
Chapter- 8: GLOBAL BIOCHIP MARKETS: MICROARRAYS AND LAB-ON-A-CHIP (BIO049D) 19
INTRODUCTION
OVERVIEW
BIOCHIP TYPES
SCOPE OF REPORT
MARKET POTENTIAL OF BIOCHIPS
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS
THE BIOCHIP INDUSTRY
SUMMARY
Table 44 : GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, THROUGH 2016
Figure 15 : GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, 2010–2016
Chapter- 9: POLYMERASE CHAIN REACTION (PCR) TECHNOLOGIES AND GLOBAL MARKETS (BIO087A) 30
INTRODUCTION
SUMMARY
MARKET DRIVERS
MARKET RESTRAINTS
OPPORTUNITIES AND CHALLENGES
MARKET OVERVIEW
EVOLUTION OF PCR TECHNOLOGY AND ITS IMPACT ON THE HEALTHCARE INDUSTRY
TRADITIONAL PCR VERSUS REAL-TIME PCR
KEY APPLICATION AREAS
PCR QUANTITATION METHODS
THE HUMAN GENOME PROJECT AND PCR
HUMAN MICROBIOME PROJECT AND PCR
TAQMAN PROBES AND MOLECULAR BEACONS: POTENTIAL ALTERNATIVES TO DYES USED IN REAL-TIME PCR
ALTERNATIVES TO PCR-BASED ANALYTICAL METHODS
KEY APPLICATION AREAS
PCR AND PUBLIC HEALTH SURVEILLANCE
EMERGING ECONOMIES AND TECHNOLOGY ADOPTION
FUTURE OF PCR
MARKET TRENDS/KEY INSIGHTS
KEY RECOMMENDATIONS/MARKET STRATEGIES
PATENT ANALYSIS
Figure 21 : PATENT ANALYSIS BY GEOGRAPHIC REGION, 2008–2010
Table L21 :
Figure 22 : PATENT ANALYSIS BY TYPE OF PRODUCT, 2008–2010
Table L22 :
List of Tables
List of Figures
Chapter- 1: 2011 BIOTECHNOLOGY RESEARCH REVIEW - Complimentary 2
FOREWORD
Chapter- 2: SAMPLE PREPARATION IN GENOMICS, PROTEOMICS, AND EPIGENOMICS: GLOBAL MARKETS (BIO089A) 16
INTRODUCTION
SUMMARY
OVERVIEW
MAJOR TRENDS AND DRIVERS IN THE SAMPLE PREP SEGMENT OF LIFE SCIENCE TOOLS INDUSTRY
GOVERNMENT POLICIES AND FUNDING
MAIN MARKET PARTICIPANTS IN THE SAMPLE PREP INDUSTRY
GEOGRAPHIC DISTRIBUTION OF THE SAMPLE PREP MARKET
TECHNOLOGY PATENTS IN THE SAMPLE PREP INDUSTRY
Chapter- 3: FLOW CYTOMETRY: PRODUCTS, TECHNOLOGIES AND GLOBAL MARKETS (BIO085A) 24
INTRODUCTION
SUMMARY
MARKET DRIVERS
RESTRAINTS
OPPORTUNITIES
MARKET OVERVIEW
EVOLUTION OF FLOW CYTOMETRY
FLOW CYTOMETRY CAPABILITY ANALYSIS
ANALYSES: KEY PLAYERS, COMPETITORS, AND MARKETS
EMERGING ECONOMIES AND TECHNOLOGY ADOPTION
STRATEGIC RECOMMENDATIONS
PATENT ANALYSIS
Figure 9 : PATENT ANALYSIS BY TYPE OF PRODUCT, 2008–2010
Table L9 :
Figure 10 : PATENTS BY GEOGRAPHY, 2008–2010
Table L10 :
Chapter- 4: BIOBANKING TECHNOLOGIES AND GLOBAL MARKETS (BIO084A) 21INTRODUCTION
SUMMARY
OVERVIEW
MODERN BIOBANKS—PUBLIC SECTOR
BIOBANKING COSTS
DRIVERS OF BIOBANKS EXPANSION
BARRIERS TO BIOBANKS EXPANSION
BIOBANKING TRENDS AND FORECAST
FORECAST FOR BIOBANK INVOLVEMENT IN FUTURE BIOMEDICAL DISCOVERIES
Chapter- 5: NEXT-GENERATION CANCER DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS (BIO081A) 14
INTRODUCTION
SUMMARY
OVERVIEW
MARKET POTENTIAL OF NEXT-GENERATION CANCER DIAGNOSTICS
FORCES DRIVING MARKET GROWTH
NEXT-GENERATION CANCER DIAGNOSTICS PLATFORMS
NEXT-GENERATION CANCER DIAGNOSTICS PRODUCT LIFE CYCLE STATUS
NEXT-GENERATION CANCER DIAGNOSTICS INDUSTRY
Table 16 : NEXT-GENERATION CANCER DIAGNOSTICS INDUSTRY
Chapter- 6: RNAI DRUG DELIVERY: TECHNOLOGIES AND GLOBAL MARKETS (BIO076A) 44
INTRODUCTION
SUMMARY
RNAI DRUG DELIVERY
CHALLENGES TO OVERCOME IN DELIVERING RNAI
DELIVERY TECHNIQUES
SUMMARY
Chapter- 7: STEM CELL THERAPEUTICS FOR ONCOLOGY: TECHNOLOGIES AND GLOBAL MARKETS (BIO075A) 21
INTRODUCTION
SUMMARY
OVERVIEW
TYPES OF CANCER
DEFINITION OF THE INDUSTRY
IMPORTANCE OF THE INDUSTRY
PRODUCT LIFE CYCLES
DEVELOPMENT OF STEM CELLS IN ONCOLOGY
FUTURE DEVELOPMENTS
WITH AN EYE TOWARD THE FUTURE
Chapter- 8: GLOBAL BIOCHIP MARKETS: MICROARRAYS AND LAB-ON-A-CHIP (BIO049D) 19
INTRODUCTION
OVERVIEW
BIOCHIP TYPES
SCOPE OF REPORT
MARKET POTENTIAL OF BIOCHIPS
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS
THE BIOCHIP INDUSTRY
SUMMARY
Table 44 : GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, THROUGH 2016
Figure 15 : GLOBAL VALUE OF BIOCHIP PRODUCTS BY END USE, 2010–2016
Chapter- 9: POLYMERASE CHAIN REACTION (PCR) TECHNOLOGIES AND GLOBAL MARKETS (BIO087A) 30
INTRODUCTION
SUMMARY
MARKET DRIVERS
MARKET RESTRAINTS
OPPORTUNITIES AND CHALLENGES
MARKET OVERVIEW
EVOLUTION OF PCR TECHNOLOGY AND ITS IMPACT ON THE HEALTHCARE INDUSTRY
TRADITIONAL PCR VERSUS REAL-TIME PCR
KEY APPLICATION AREAS
PCR QUANTITATION METHODS
THE HUMAN GENOME PROJECT AND PCR
HUMAN MICROBIOME PROJECT AND PCR
TAQMAN PROBES AND MOLECULAR BEACONS: POTENTIAL ALTERNATIVES TO DYES USED IN REAL-TIME PCR
ALTERNATIVES TO PCR-BASED ANALYTICAL METHODS
KEY APPLICATION AREAS
PCR AND PUBLIC HEALTH SURVEILLANCE
EMERGING ECONOMIES AND TECHNOLOGY ADOPTION
FUTURE OF PCR
MARKET TRENDS/KEY INSIGHTS
KEY RECOMMENDATIONS/MARKET STRATEGIES
PATENT ANALYSIS
Figure 21 : PATENT ANALYSIS BY GEOGRAPHIC REGION, 2008–2010
Table L21 :
Figure 22 : PATENT ANALYSIS BY TYPE OF PRODUCT, 2008–2010
Table L22 :
List of Tables
List of Figures
No comments:
Post a Comment